<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741506</url>
  </required_header>
  <id_info>
    <org_study_id>COPPVATS vs 1.1</org_study_id>
    <secondary_id>2012-002409-23</secondary_id>
    <nct_id>NCT01741506</nct_id>
  </id_info>
  <brief_title>Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer</brief_title>
  <acronym>COPPVATS</acronym>
  <official_title>Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Decker Christensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is:

      To estimate patients with lung cancers who will undergo surgery total haemostatic /
      thrombotic capacity pre, per-and postoperatively.

      To investigate whether prophylactic treatment with Low Molecular Weight Heparin (LMWH)
      affects the patient's potential hypercoagulability.

      To investigate whether there are differences in patients who will undergo Video Assisted
      Thorascopic Surgery (VATS) or open surgery in regards of impact of the coagulation system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is a serious and very frequent disease. For those 25% of the patients who will
      undergo surgery, there are two different methods of operation: either open surgery
      (thoracotomy) or Video Assisted Thorascopic Surgery (VATS). The latter method is increasing
      in use.

      Patients are often prescribed heparin pre- postoperatively, but it is unclear whether this
      prophylactic treatment is necessary, and it has never been thoroughly investigated.

      When patients receive heparin there is an increased risk of bleeding.

      Furthermore, it is unclear what changes occurs in the coagulation system pre, per- and
      postoperatively in patients undergoing surgery for lung-cancer, and hereby it is unclear
      whether these patients should have some sort of medical prophylactic treatment.

      By using new analysis methods in terms of Thromboelastometry, Thrombin generation and
      thrombocyte function analysis, hereby the total coagulation profile can be characterized and
      hereby estimate the risk of thrombosis and bleeding. Thereby better be able to give the right
      treatment for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboelastometry (ROTEM®)</measure>
    <time_frame>30 days</time_frame>
    <description>Analysis of in-tem, ex-tem, fib-tem og hep-tem and estimation of: Clotting time (CT (sec)), propagation (MaxVel (mm*100/sec) t,MaxVel, s) og termination (maximum clot firmness (MCF)(mm*100/sec)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation</measure>
    <time_frame>30 days</time_frame>
    <description>1) recalcificering, 2) activation with tissue factor 1:17,000 and estimation of Lag time [min], ETP (endogenous thrombin potential) [nM (nanomole) thrombin*minute], peak levels of thrombin generation [nM thrombin] and time to peak thrombin (ttpeak) [min].</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Standard coagulation analysis</measure>
    <time_frame>30 days</time_frame>
    <description>APTT (activated partial thromboplastin time), INR (International Normalized Ratio), fibrinogen, fibrin d-dimer, thrombin time, thrombocytes and Factor VIII: clot.</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombocyte function analysis</measure>
    <time_frame>30 days</time_frame>
    <description>analysis on Multiplate®, where the thrombocyte aggregation are expressed as Aggregation unit (AU), area under curve (A*min).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dalteparin (Fragmin®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dalteparin (Fragmin®) 5000 IU (International Unit) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open surgery arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dalteparin (Fragmin®) 5000 IU once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin (Fragmin®)</intervention_name>
    <arm_group_label>Dalteparin (Fragmin®)</arm_group_label>
    <arm_group_label>Open surgery arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergo surgery for lung cancer with an expected lobectomy or bilobectomy

          -  The surgery shall be VATS (for patients in the group randomized to other low molecular
             weight heparin and no prophylactic)

          -  Willing to be randomized (VATS-patients)

          -  Over 18 years old.

          -  Able to give assigned informed consent

          -  Women should be prescribed secure anticonception.

        Exclusion Criteria:

          -  Thromboembolic events within the last three months (both venous and arterial)

          -  Pregnant

          -  Lactating

          -  Treatment with anticoagulation therapy in terms of vitamin K antagonist or direct or
             indirect thrombin inhibitors (dabigatran, apixaban or rivaroxaban)

          -  Treatment with thrombocyte function inhibitors in terms of Clopidogrel, ASA
             (acetylsalicylic acid), prasugrel and ticagrelor, and no pause of minimum 5 days (7
             days with regards of prasugrel) before surgery

          -  Allergy for LMWH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas D Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Decker Christensen</investigator_full_name>
    <investigator_title>Senior staff surgeon, MD, DMSc, PhD</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

